[Dapagliflozin, a novel oral antidiabetic with an uncertain future].

CONCLUSIONS: Dapagliflozin does not provide advantages over pharmacotherapy for DM2. Its lack of experience of use, the absence of significant clinical benefits and its high cost make it necessary to restrict its use.
PMID: 25542657 [PubMed - in process]

Source: Farmacia Hospitalaria - November 1, 2014 Category: Drugs & Pharmacology Authors: Escudero Vilaplana B, Almodóvar Carretón MJ, Herrero Hernández S Tags: Farm Hosp Source Type: research